Patents by Inventor Francine Zhifen Chen

Francine Zhifen Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bi-specific monovalent diabodies that are capable of binding to gpA33 and CD3, and uses thereof
    Patent number: 10858430
    Abstract: The present invention is directed to bi-specific monovalent diabodies that comprise two polypeptide chains and which possess at least one binding site specific for an epitope of CD3 and one binding site specific for an epitope of gpA33 (i.e., a “gpA33×CD3 bi-specific monovalent diabody”). The present invention also is directed to bi-specific monovalent diabodies that comprise an immunoglobulin Fc Domain (“bi-specific monovalent Fc diabodies”) and are composed of three polypeptide chains and which possess at least one binding site specific for an epitope of gpA33 and one binding site specific for an epitope of CD3 (i.e., a “gpA33×CD3 bi-specific monovalent Fc diabody”). The bi-specific monovalent diabodies and bi-specific monovalent Fc diabodies of the present invention are capable of simultaneous binding to gpA33 and CD3. The invention is directed to pharmaceutical compositions that contain such bi-specific monovalent diabodies or such bi-specific monovalent Fc diabodies.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: December 8, 2020
    Assignee: MacroGenics, Inc.
    Inventors: Paul A. Moore, Jonathan Li, Francine Zhifen Chen, Leslie S. Johnson, Kalpana Shah, Ezio Bonvini
  • Antibodies Reactive with B7-H3, Immunologically Active Fragments Thereof and Uses Thereof
    Publication number: 20200377612
    Abstract: The present invention relates to antibodies and their fragments that are immunoreactive to the mammalian, and more particularly, the human B7-H3 receptor and to uses thereof, particularly in the treatment of cancer and inflammation. The invention thus particularly concerns humanized B7-H3-reactive antibodies and their immunoreactive fragments that are capable of mediating, and more preferably enhancing the activation of the immune system against cancer cells that are associated with a variety of human cancers.
    Type: Application
    Filed: May 7, 2020
    Publication date: December 3, 2020
    Applicant: MacroGenics, Inc.
    Inventors: Leslie S. Johnson, Paul A. Moore, Ling Huang, Deryk T. Loo, Francine Zhifen Chen
  • Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof
    Patent number: 10683364
    Abstract: The present invention relates to antibodies and their fragments that are immunoreactive to the mammalian, and more particularly, the human B7-H3 receptor and to uses thereof, particularly in the treatment of cancer and inflammation. The invention thus particularly concerns humanized B7-H3-reactive antibodies and their immunoreactive fragments that are capable of mediating, and more preferably enhancing the activation of the immune system against cancer cells that are associated with a variety of human cancers.
    Type: Grant
    Filed: June 19, 2017
    Date of Patent: June 16, 2020
    Assignee: MacroGenics, Inc.
    Inventors: Leslie S. Johnson, Paul A. Moore, Ling Huang, Deryk T. Loo, Francine Zhifen Chen
  • Bi-Specific Monovalent Diabodies That are Capable of Binding to gpA33 and CD3, and Uses Thereof
    Publication number: 20180118824
    Abstract: The present invention is directed to bi-specific monovalent diabodies that comprise two polypeptide chains and which possess at least one binding site specific for an epitope of CD3 and one binding site specific for an epitope of gpA33 (i.e., a “gpA33×CD3 bi-specific monovalent diabody”). The present invention also is directed to bi-specific monovalent diabodies that comprise an immunoglobulin Fc Domain (“bi-specific monovalent Fc diabodies”) and are composed of three polypeptide chains and which possess at least one binding site specific for an epitope of gpA33 and one binding site specific for an epitope of CD3 (i.e., a “gpA33×CD3 bi-specific monovalent Fc diabody”). The bi-specific monovalent diabodies and bi-specific monovalent Fc diabodies of the present invention are capable of simultaneous binding to gpA33 and CD3. The invention is directed to pharmaceutical compositions that contain such bi-specific monovalent diabodies or such bi-specific monovalent Fc diabodies.
    Type: Application
    Filed: November 21, 2017
    Publication date: May 3, 2018
    Applicant: MacroGenics, Inc.
    Inventors: Paul A. Moore, Jonathan Li, Francine Zhifen Chen, Leslie S. Johnson, Kalpana Shah, Ezio Bonvini
  • Bi-specific monovalent diabodies that are capable of binding to gpA33 and CD3, and uses thereof
    Patent number: 9932400
    Abstract: The present invention is directed to bi-specific monovalent diabodies that comprise two polypeptide chains and which possess at least one binding site specific for an epitope of CD3 and one binding site specific for an epitope of gpA33 (i.e., a “gpA33×CD3 bi-specific monovalent diabody”). The present invention also is directed to bi-specific monovalent diabodies that comprise an immunoglobulin Fc Domain (“bi-specific monovalent Fc diabodies”) and are composed of three polypeptide chains and which possess at least one binding site specific for an epitope of gpA33 and one binding site specific for an epitope of CD3 (i.e., a “gpA33×CD3 bi-specific monovalent Fc diabody”). The bi-specific monovalent diabodies and bi-specific monovalent Fc diabodies of the present invention are capable of simultaneous binding to gpA33 and CD3. The invention is directed to pharmaceutical compositions that contain such bi-specific monovalent diabodies or such bi-specific monovalent Fc diabodies.
    Type: Grant
    Filed: August 20, 2014
    Date of Patent: April 3, 2018
    Assignee: MacroGenics, Inc.
    Inventors: Paul A. Moore, Jonathan Li, Francine Zhifen Chen, Leslie S. Johnson, Kalpana Shah, Ezio Bonvini
  • Antibodies reactive with B7-H3 and uses thereof
    Patent number: 9896508
    Abstract: The present invention relates to antibodies that are immunoreactive to the mammalian, and more particularly, the human B7-H3 receptor and to uses thereof, particularly in the treatment of cancer and inflammation. The invention thus particularly concerns humanized B7-H3-reactive antibodies that are capable of mediating, and more preferably enhancing the activation of the immune system against cancer cells that are associated with a variety of human cancers.
    Type: Grant
    Filed: May 31, 2016
    Date of Patent: February 20, 2018
    Assignee: MacroGenics, Inc.
    Inventors: Leslie S. Johnson, Ling Huang, Paul A. Moore, Deryk T. Loo, Francine Zhifen Chen
  • Antibodies Reactive with B7-H3, Immunologically Active Fragments Thereof and Uses Thereof
    Publication number: 20170362333
    Abstract: The present invention relates to antibodies and their fragments that are immunoreactive to the mammalian, and more particularly, the human B7-H3 receptor and to uses thereof, particularly in the treatment of cancer and inflammation. The invention thus particularly concerns humanized B7-H3-reactive antibodies and their immunoreactive fragments that are capable of mediating, and more preferably enhancing the activation of the immune system against cancer cells that are associated with a variety of human cancers.
    Type: Application
    Filed: June 19, 2017
    Publication date: December 21, 2017
    Applicant: MacroGenics, Inc.
    Inventors: Leslie S. Johnson, Paul A. Moore, Ling Huang, Deryk T. Loo, Francine Zhifen Chen
  • Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof
    Patent number: 9714295
    Abstract: The present invention relates to antibodies and their fragments that are immunoreactive to the mammalian, and more particularly, the human B7-H3 receptor and to uses thereof, particularly in the treatment of cancer and inflammation. The invention thus particularly concerns humanized B7-H3-reactive antibodies and their immunoreactive fragments that are capable of mediating, and more preferably enhancing the activation of the immune system against cancer cells that are associated with a variety of human cancers.
    Type: Grant
    Filed: June 1, 2015
    Date of Patent: July 25, 2017
    Assignee: MacroGenics, Inc.
    Inventors: Leslie S. Johnson, Paul A. Moore, Ling Huang, Deryk T. Loo, Francine Zhifen Chen
  • Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof
    Patent number: 9714296
    Abstract: The present invention relates to antibodies and their fragments that are immunoreactive to the mammalian, and more particularly, the human B7-H3 receptor and to uses thereof, particularly in the treatment of cancer and inflammation. The invention thus particularly concerns humanized B7-H3-reactive antibodies and their immunoreactive fragments that are capable of mediating, and more preferably enhancing the activation of the immune system against cancer cells that are associated with a variety of human cancers.
    Type: Grant
    Filed: June 1, 2015
    Date of Patent: July 25, 2017
    Assignee: MacroGenics, Inc.
    Inventors: Leslie S. Johnson, Paul A. Moore, Ling Huang, Deryk T. Loo, Francine Zhifen Chen
  • Antibodies Reactive with B7-H3 and Uses Thereof
    Publication number: 20160264672
    Abstract: The present invention relates to antibodies that are immunoreactive to the mammalian, and more particularly, the human B7-H3 receptor and to uses thereof, particularly in the treatment of cancer and inflammation. The invention thus particularly concerns humanized B7-H3-reactive antibodies that are capable of mediating, and more preferably enhancing the activation of the immune system against cancer cells that are associated with a variety of human cancers.
    Type: Application
    Filed: May 31, 2016
    Publication date: September 15, 2016
    Applicant: MacroGenics, Inc.
    Inventors: Leslie S. Johnson, Ling Huang, Paul A. Moore, Deryk T. Loo, Francine Zhifen Chen
  • Bi-Specific Monovalent Diabodies That are Capable of Binding to gpA33 and CD3, and Uses Thereof
    Publication number: 20160222105
    Abstract: The present invention is directed to bi-specific monovalent diabodies that comprise two polypeptide chains and which possess at least one binding site specific for an epitope of CD3 and one binding site specific for an epitope of gpA33 (i.e., a “gpA33×CD3 bi-specific monovalent diabody”). The present invention also is directed to bi-specific monovalent diabodies that comprise an immunoglobulin Fc Domain (“bi-specific monovalent Fc diabodies”) and are composed of three polypeptide chains and which possess at least one binding site specific for an epitope of gpA33 and one binding site specific for an epitope of CD3 (i.e., a “gpA33×CD3 bi-specific monovalent Fc diabody”). The bi-specific monovalent diabodies and bi-specific monovalent Fc diabodies of the present invention are capable of simultaneous binding to gpA33 and CD3. The invention is directed to pharmaceutical compositions that contain such bi-specific monovalent diabodies or such bi-specific monovalent Fc diabodies.
    Type: Application
    Filed: August 20, 2014
    Publication date: August 4, 2016
    Applicant: MacroGenics, Inc.
    Inventors: Paul A. Moore, Jonathan Li, Francine Zhifen Chen, Leslie S. Johnson, Kalpana Shah, Ezio Bonvini
  • Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof
    Patent number: 9150656
    Abstract: The present invention relates to antibodies and their fragments that are immunoreactive to the mammalian, and more particularly, the human B7-H3 receptor and to uses thereof, particularly in the treatment of cancer and inflammation. The invention thus particularly concerns humanized B7-H3-reactive antibodies and their immunoreactive fragments that are capable of mediating, and more preferably enhancing the activation of the immune system against cancer cells that are associated with a variety of human cancers.
    Type: Grant
    Filed: March 1, 2011
    Date of Patent: October 6, 2015
    Assignee: MacroGenics, Inc.
    Inventors: Leslie S. Johnson, Paul A. Moore, Ling Huang, Deryk T. Loo, Francine Zhifen Chen
  • Antibodies Reactive with B7-H3, Immunologically Active Fragments Thereof and Uses Thereof
    Publication number: 20130149236
    Abstract: The present invention relates to antibodies and their fragments that are immunoreactive to the mammalian, and more particularly, the human B7-H3 receptor and to uses thereof, particularly in the treatment of cancer and inflammation. The invention thus particularly concerns humanized B7-H3-reactive antibodies and their immunoreactive fragments that are capable of mediating, and more preferably enhancing the activation of the immune system against cancer cells that are associated with a variety of human cancers.
    Type: Application
    Filed: March 1, 2011
    Publication date: June 13, 2013
    Applicant: MACROGENICS, INC.
    Inventors: Leslie S. Johnson, Paul A. Moore, Ling Huang, Deryk T. Loo, Francine Zhifen Chen